Cargando…

True prevalence of long-COVID in a nationwide, population cohort study

Long-COVID prevalence estimates vary widely and should take account of symptoms that would have occurred anyway. Here we determine the prevalence of symptoms attributable to SARS-CoV-2 infection, taking account of background rates and confounding, in a nationwide population cohort study of 198,096 S...

Descripción completa

Detalles Bibliográficos
Autores principales: Hastie, Claire E., Lowe, David J., McAuley, Andrew, Mills, Nicholas L., Winter, Andrew J., Black, Corri, Scott, Janet T., O’Donnell, Catherine A., Blane, David N., Browne, Susan, Ibbotson, Tracy R., Pell, Jill P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689486/
https://www.ncbi.nlm.nih.gov/pubmed/38036541
http://dx.doi.org/10.1038/s41467-023-43661-w
_version_ 1785152378178109440
author Hastie, Claire E.
Lowe, David J.
McAuley, Andrew
Mills, Nicholas L.
Winter, Andrew J.
Black, Corri
Scott, Janet T.
O’Donnell, Catherine A.
Blane, David N.
Browne, Susan
Ibbotson, Tracy R.
Pell, Jill P.
author_facet Hastie, Claire E.
Lowe, David J.
McAuley, Andrew
Mills, Nicholas L.
Winter, Andrew J.
Black, Corri
Scott, Janet T.
O’Donnell, Catherine A.
Blane, David N.
Browne, Susan
Ibbotson, Tracy R.
Pell, Jill P.
author_sort Hastie, Claire E.
collection PubMed
description Long-COVID prevalence estimates vary widely and should take account of symptoms that would have occurred anyway. Here we determine the prevalence of symptoms attributable to SARS-CoV-2 infection, taking account of background rates and confounding, in a nationwide population cohort study of 198,096 Scottish adults. 98,666 (49.8%) had symptomatic laboratory-confirmed SARS-CoV-2 infections and 99,430 (50.2%) were age-, sex-, and socioeconomically-matched and never-infected. While 41,775 (64.5%) reported at least one symptom 6 months following SARS-CoV-2 infection, this was also true of 34,600 (50.8%) of those never-infected. The crude prevalence of one or more symptom attributable to SARS-CoV-2 infection was 13.8% (13.2%,14.3%), 12.8% (11.9%,13.6%), and 16.3% (14.4%,18.2%) at 6, 12, and 18 months respectively. Following adjustment for potential confounders, these figures were 6.6% (6.3%, 6.9%), 6.5% (6.0%, 6.9%) and 10.4% (9.1%, 11.6%) respectively. Long-COVID is characterised by a wide range of symptoms that, apart from altered taste and smell, are non-specific. Care should be taken in attributing symptoms to previous SARS-CoV-2 infection.
format Online
Article
Text
id pubmed-10689486
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106894862023-12-02 True prevalence of long-COVID in a nationwide, population cohort study Hastie, Claire E. Lowe, David J. McAuley, Andrew Mills, Nicholas L. Winter, Andrew J. Black, Corri Scott, Janet T. O’Donnell, Catherine A. Blane, David N. Browne, Susan Ibbotson, Tracy R. Pell, Jill P. Nat Commun Article Long-COVID prevalence estimates vary widely and should take account of symptoms that would have occurred anyway. Here we determine the prevalence of symptoms attributable to SARS-CoV-2 infection, taking account of background rates and confounding, in a nationwide population cohort study of 198,096 Scottish adults. 98,666 (49.8%) had symptomatic laboratory-confirmed SARS-CoV-2 infections and 99,430 (50.2%) were age-, sex-, and socioeconomically-matched and never-infected. While 41,775 (64.5%) reported at least one symptom 6 months following SARS-CoV-2 infection, this was also true of 34,600 (50.8%) of those never-infected. The crude prevalence of one or more symptom attributable to SARS-CoV-2 infection was 13.8% (13.2%,14.3%), 12.8% (11.9%,13.6%), and 16.3% (14.4%,18.2%) at 6, 12, and 18 months respectively. Following adjustment for potential confounders, these figures were 6.6% (6.3%, 6.9%), 6.5% (6.0%, 6.9%) and 10.4% (9.1%, 11.6%) respectively. Long-COVID is characterised by a wide range of symptoms that, apart from altered taste and smell, are non-specific. Care should be taken in attributing symptoms to previous SARS-CoV-2 infection. Nature Publishing Group UK 2023-11-30 /pmc/articles/PMC10689486/ /pubmed/38036541 http://dx.doi.org/10.1038/s41467-023-43661-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Hastie, Claire E.
Lowe, David J.
McAuley, Andrew
Mills, Nicholas L.
Winter, Andrew J.
Black, Corri
Scott, Janet T.
O’Donnell, Catherine A.
Blane, David N.
Browne, Susan
Ibbotson, Tracy R.
Pell, Jill P.
True prevalence of long-COVID in a nationwide, population cohort study
title True prevalence of long-COVID in a nationwide, population cohort study
title_full True prevalence of long-COVID in a nationwide, population cohort study
title_fullStr True prevalence of long-COVID in a nationwide, population cohort study
title_full_unstemmed True prevalence of long-COVID in a nationwide, population cohort study
title_short True prevalence of long-COVID in a nationwide, population cohort study
title_sort true prevalence of long-covid in a nationwide, population cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689486/
https://www.ncbi.nlm.nih.gov/pubmed/38036541
http://dx.doi.org/10.1038/s41467-023-43661-w
work_keys_str_mv AT hastieclairee trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT lowedavidj trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT mcauleyandrew trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT millsnicholasl trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT winterandrewj trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT blackcorri trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT scottjanett trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT odonnellcatherinea trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT blanedavidn trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT brownesusan trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT ibbotsontracyr trueprevalenceoflongcovidinanationwidepopulationcohortstudy
AT pelljillp trueprevalenceoflongcovidinanationwidepopulationcohortstudy